Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b

Table 2 Significant factors independently contribute to ΔTC, ΔLDL-C at 4 wk of therapy

	B	SE	P value
ΔTC at 4W
Constant	19.79	12.10	0.103
Therapy protocol (DCV + ASV: 0, SOF + LDV:1)	22.44	2.45	< 0.001
ALT	-0.065	0.03	0.033
HCV-RNA	4.540	1.50	0.003
Alb	-9.630	2.53	< 0.001
ΔLDL-C at 4W
Constant	49.38	11.32	< 0.001
Therapy protocol (DCV + ASV: 0, SOF + LDV:1)	17.5	2.40	< 0.001
Alb	-10.67	2.68	< 0.001
T-Bil	-12.17	2.82	< 0.001
TG	0.063	0.016	< 0.001

Choice of therapy protocol (DCA-ASV or SOF + LDV) was commonly selected as an independent predictor significantly associated with ΔTC, ΔLDL-C at 4 wk of therapy. TC: Total cholesterol; TG: Triglyceride; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; ALT: Alanine-2-oxoglutarate aminotransferase; HCV-RNA: Hepatitis C virus ribonucleic acid; Alb: Albumin; T.Bil: Total bilirubin; PT: Prothrombin time.